Whether it’s part of an over 75 health assessment or fitness to drive assessment, investigating patients’ concerns about impairment, or tracking progress over time, cognitive screening is important.
As we journey through life, the risk of developing chronic diseases, including cancer, heart disease and neurological disorders, increases significantly.
Attention deficit-hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects 2.5–5% of people. Less than half of people with ADHD have been diagnosed and treated – though more and more people are presenting for help.
Plasma biomarkers have now been clinically validated, which could make biological diagnosis of Alzheimer’s disease more accessible. Previously MRI, PET scanning or CSF assays were needed to make a biological diagnosis.
In this Product Explainer, Pharmacist Dr Jacinta Johnson explains the schedule 3 supply of triptans as Pharmacist Only Medicine, and presents several considerations when choosing the appropriate triptan for the acute management of migraine (6 mins).
At the same time as it has attracted support and understanding, attention deficit hyperactivity disorder (ADHD) has invoked passionate debate in recent years. One hot topic is whether ADHD is being over-diagnosed.
Tune in for "Facial rashes case studies - Practical guide to assessment and management" lecture
Tuesday 9th June, 7pm - 9pm AEST
Speaker
Dr Philip Tong
Consultant Dermatologist; Founder, DermScreen, Dermatology Junction; Visiting Medical Officer, St Vincent’s Hospital Sydney
What does it mean when a facial red rash does not respond to topical steroids and gets worse with the treatment? Dermatologist Dr Philip Tong presents a series of cases with this scenario.